A phase Ib, open-label, multicenter, single arm study evaluating the preliminary efficacy, safety, and pharmacokinetics of Glofitamab in combination with Rituximab plus Ifosfamide, Carboplatin Etoposide Phosphate in patients with relapsed/ refractory transplant or CAR-T therapy eligible diffuse B-Cell Lymphoma

Description

The purpose of this study is to evaluate the preliminary efficacy, safety, and pharmacokinetics of glofitamab (glofit) in combination with rituximab plus ifosfamide, carboplatin, and etoposide (R-ICE) in participants with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who have failed one prior line of therapy incorporating an anti-cluster of differentiation (CD) 20 antibody (i.e., rituximab) and an anthracycline, and who are transplant or chimeric antigen receptor T-cell (CAR-T) therapy eligible, defined as being medically eligible for intensive platinum-based salvage therapy followed by autologous stem cell transplantation (ASCT) or for CAR-T therapy.

Resources and Links

Phone Number: 1-877-MDA-6789

clinicaltrials.gov NCT No: NCT05364424 Opens a new window